Benchtop bioreactors market seen reaching $1.75 billion by 2030
The global benchtop bioreactors market is expected to grow from $1.19 billion in 2026 to $1.75 billion by 2030, driven by biologics, biosimilars, and gene therapy research. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.
Why it matters: - Benchtop bioreactors are becoming more important in drug development, gene therapy research, and lab-scale biomanufacturing. - The market’s growth signals rising demand for controlled, small-scale systems that support both research and early production. - The expansion could benefit academic labs, pharmaceutical developers, and contract research organizations working on biologics and cell-based therapies.
What happened: - The global benchtop bioreactors market is projected to rise from $1.08 billion in 2025 to $1.19 billion in 2026. - The market is forecast to reach $1.75 billion by 2030. - The Business Research Company estimates a 10.2% CAGR across the historical period and a 10.1% CAGR over the forecast period. - The report is titled Benchtop Bioreactors Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region in the coming years.
The details: - Benchtop bioreactors are compact laboratory vessels used to cultivate cells, microorganisms, or tissues under controlled conditions. - These systems regulate temperature, pH, and oxygen levels to support growth and product output. - Growth in the market has been linked to higher life sciences research spending, more academic and research institutions, small-scale fermentation use, stronger pharmaceutical R&D, and demand for controlled lab environments. - The forecast period is also tied to growth in biologics and biosimilar development, wider adoption of automated and continuous bioreactors, and more personalized medicine research. - The report also points to stronger collaboration with contract research organizations and ongoing bioprocessing advances. - Trend areas include more R&D use, higher demand for single-use and modular systems, process optimization, cell culture and microbial fermentation studies, and use in academic training. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The company added market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics, and updated graphics and tables to its 2026 reports.
Between the lines: - Gene therapy is emerging as a major demand driver because it requires precise, repeatable production of gene-modified cells. - The American Society of Gene & Cell Therapy reported in December 2024 that the FDA approved six gene therapy products in 2023, up from five in 2022. - That approval trend helps explain why benchtop bioreactors are gaining importance in gene therapy R&D and small-scale manufacturing.
What's next: - Demand should continue rising as biologics pipelines expand and more labs adopt automated and single-use bioreactor systems. - Asia-Pacific growth may outpace other regions as research and bioprocessing capacity expands. - More use in personalized medicine and CRO-supported development could add further momentum. - A free sample of the report is available here. - The full report is available here.
The bottom line: - Benchtop bioreactors are moving from a niche lab tool to a more central platform for research, development, and early-stage biomanufacturing.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Asia News Digest
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.